vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
Smith Douglas Homes Corp. is the larger business by last-quarter revenue ($260.4M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). Smith Douglas Homes Corp. runs the higher net margin — 1.4% vs -0.7%, a 2.1% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -9.4%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $8.7M). Over the past eight quarters, Smith Douglas Homes Corp.'s revenue compounded faster (17.3% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
AVNS vs SDHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $260.4M |
| Net Profit | $-1.3M | $3.5M |
| Gross Margin | 47.5% | 19.9% |
| Operating Margin | 1.4% | 6.5% |
| Net Margin | -0.7% | 1.4% |
| Revenue YoY | 0.7% | -9.4% |
| Net Profit YoY | 99.7% | -14.3% |
| EPS (diluted) | $-0.02 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $260.4M | ||
| Q3 25 | $177.8M | $262.0M | ||
| Q2 25 | $175.0M | $223.9M | ||
| Q1 25 | $167.5M | $224.7M | ||
| Q4 24 | $179.6M | $287.5M | ||
| Q3 24 | $170.4M | $277.8M | ||
| Q2 24 | $171.7M | $220.9M | ||
| Q1 24 | $166.1M | $189.2M |
| Q4 25 | $-1.3M | $3.5M | ||
| Q3 25 | $-1.4M | $2.1M | ||
| Q2 25 | $-76.8M | $2.4M | ||
| Q1 25 | $6.6M | $2.7M | ||
| Q4 24 | $-397.3M | $4.1M | ||
| Q3 24 | $4.3M | $5.3M | ||
| Q2 24 | $1.8M | $3.6M | ||
| Q1 24 | $-900.0K | $3.0M |
| Q4 25 | 47.5% | 19.9% | ||
| Q3 25 | 48.4% | 21.0% | ||
| Q2 25 | 52.6% | 23.2% | ||
| Q1 25 | 53.6% | 23.8% | ||
| Q4 24 | 54.6% | 25.5% | ||
| Q3 24 | 54.5% | 26.5% | ||
| Q2 24 | 55.7% | 26.7% | ||
| Q1 24 | 57.1% | 26.1% |
| Q4 25 | 1.4% | 6.5% | ||
| Q3 25 | 0.1% | 6.6% | ||
| Q2 25 | -42.6% | 7.7% | ||
| Q1 25 | 6.1% | 8.7% | ||
| Q4 24 | -233.0% | 10.4% | ||
| Q3 24 | 7.0% | 14.2% | ||
| Q2 24 | 3.7% | 11.7% | ||
| Q1 24 | 2.4% | 11.3% |
| Q4 25 | -0.7% | 1.4% | ||
| Q3 25 | -0.8% | 0.8% | ||
| Q2 25 | -43.9% | 1.1% | ||
| Q1 25 | 3.9% | 1.2% | ||
| Q4 24 | -221.2% | 1.4% | ||
| Q3 24 | 2.5% | 1.9% | ||
| Q2 24 | 1.0% | 1.7% | ||
| Q1 24 | -0.5% | 1.6% |
| Q4 25 | $-0.02 | $0.39 | ||
| Q3 25 | $-0.03 | $0.24 | ||
| Q2 25 | $-1.66 | $0.26 | ||
| Q1 25 | $0.14 | $0.30 | ||
| Q4 24 | $-8.64 | $0.50 | ||
| Q3 24 | $0.09 | $0.58 | ||
| Q2 24 | $0.04 | $0.40 | ||
| Q1 24 | $-0.02 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $12.7M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $86.7M |
| Total Assets | $1.1B | $557.6M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $12.7M | ||
| Q3 25 | $70.5M | $14.8M | ||
| Q2 25 | $90.3M | $16.8M | ||
| Q1 25 | $97.0M | $12.7M | ||
| Q4 24 | $107.7M | $22.4M | ||
| Q3 24 | $89.0M | $23.7M | ||
| Q2 24 | $92.2M | $17.3M | ||
| Q1 24 | $75.8M | $32.8M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $86.7M | ||
| Q3 25 | $778.0M | $82.2M | ||
| Q2 25 | $776.3M | $80.0M | ||
| Q1 25 | $839.4M | $76.9M | ||
| Q4 24 | $828.5M | $73.6M | ||
| Q3 24 | $1.2B | $68.4M | ||
| Q2 24 | $1.2B | $62.1M | ||
| Q1 24 | $1.2B | $59.7M |
| Q4 25 | $1.1B | $557.6M | ||
| Q3 25 | $1.1B | $571.6M | ||
| Q2 25 | $1.0B | $570.2M | ||
| Q1 25 | $1.1B | $513.9M | ||
| Q4 24 | $1.2B | $475.9M | ||
| Q3 24 | $1.7B | $460.1M | ||
| Q2 24 | $1.7B | $429.3M | ||
| Q1 24 | $1.7B | $401.3M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $9.8M |
| Free Cash FlowOCF − Capex | $21.3M | $8.7M |
| FCF MarginFCF / Revenue | 11.8% | 3.4% |
| Capex IntensityCapex / Revenue | 3.8% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $9.8M | ||
| Q3 25 | $14.0M | $22.8M | ||
| Q2 25 | $6.8M | $-28.9M | ||
| Q1 25 | $25.7M | $-34.9M | ||
| Q4 24 | $57.9M | $5.5M | ||
| Q3 24 | $23.0M | $22.9M | ||
| Q2 24 | $27.8M | $39.0K | ||
| Q1 24 | $-8.0M | $-9.3M |
| Q4 25 | $21.3M | $8.7M | ||
| Q3 25 | $7.0M | $21.4M | ||
| Q2 25 | $-4.2M | $-31.1M | ||
| Q1 25 | $19.0M | $-35.9M | ||
| Q4 24 | $53.1M | $4.8M | ||
| Q3 24 | $20.0M | $22.3M | ||
| Q2 24 | $21.9M | $-2.1M | ||
| Q1 24 | $-12.1M | $-9.7M |
| Q4 25 | 11.8% | 3.4% | ||
| Q3 25 | 3.9% | 8.2% | ||
| Q2 25 | -2.4% | -13.9% | ||
| Q1 25 | 11.3% | -16.0% | ||
| Q4 24 | 29.6% | 1.7% | ||
| Q3 24 | 11.7% | 8.0% | ||
| Q2 24 | 12.8% | -1.0% | ||
| Q1 24 | -7.3% | -5.1% |
| Q4 25 | 3.8% | 0.4% | ||
| Q3 25 | 3.9% | 0.5% | ||
| Q2 25 | 6.3% | 0.9% | ||
| Q1 25 | 4.0% | 0.5% | ||
| Q4 24 | 2.7% | 0.2% | ||
| Q3 24 | 1.8% | 0.2% | ||
| Q2 24 | 3.4% | 1.0% | ||
| Q1 24 | 2.5% | 0.2% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | 10.70× | ||
| Q2 25 | — | -12.24× | ||
| Q1 25 | 3.89× | -13.01× | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | 5.35× | 4.28× | ||
| Q2 24 | 15.44× | 0.01× | ||
| Q1 24 | — | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
